Kidney transplantation remains limited by organ shortage, with increasing focus on improving deceased donor kidney utilization.1,2 In the era of direct-acting antiviral agents (DAA), the demonstration of successful transplantation of kidneys from viremic donors with positive hepatitis C nucleic acid testing (HCV-NAT+) was a major breakthrough with the potential to significantly increase the number of transplants, given that kidneys from donors with HCV have been at high risk for discard.3-5 A growing number of recent publications have demonstrated the safety and efficacy of HCV-NAT+ deceased donor kidney transplantation in recipients with or without HCV (Table S1).